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 CURRENTOPINION The role of antimullerian hormone in
assessing ovarian damage from chemotherapy,
radiotherapy and surgery
Queenie Ho Yan Wonga,b and Richard A. Andersonc
Purpose of review
Iatrogenic ovarian damage can occur after chemotherapy, radiotherapy and surgery for cancer as well as
for non-malignant conditions. This review describes the effects of such treatment on antimullerian hormone
(AMH) and the implications of the fall in AMH in relation to ovarian function and fertility, especially in the
era of improved fertility preservation strategies.
Recent findings
The risk of gonadotoxicity differs between chemotherapy regimens. There is growing evidence that
pretreatment AMH has prognostic significance for the degree of fall in AMH after treatment, the
reversibility of ovarian damage and risk of premature ovarian insufficiency. The accuracy of prediction
increases when age is coupled with AMH. The adverse effect of removal of endometriomas is increasingly
clear, and AMH pre and post surgery useful is assessing the degree of damage to the ovary. The
implications of low AMH after such treatment on natural fertility and reproductive lifespan are less clear.
Apart from treatment effects, there are other coexisting conditions that can affect AMH which needs to be
taken into consideration during interpretation of AMH before and after treatment.
Summary
A fall in AMH in women after gonadotoxic treatment has been consistently described, with variable recovery,
the accurate interpretation and clinical application of post-treatment AMH level on reproductive lifespan and
fertility prediction needs to be studied in future larger prospective studies with longer follow-up.
Keywords
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INTRODUCTION
Iatrogenic ovarian damage can occur with chemo-
therapy, radiotherapy and surgery for cancer, for
non-malignant conditions such as conditioning
for stem cell transplant in haematological diseases,
and in gynaecological conditions such as endome-
triosis. Depending on age at treatment, impairment
of ovarian function because of accelerated depletion
of primordial follicles has implications for puberty,
fertility and the long-term health consequences of
oestrogen deficiency as it may result in a woman
living more than half her life in a postmenopausal
state. It is important for clinicians to be able to
detect and perhaps predict ovarian impairment
early to optimize the management of these girls
and women, allowing fertility preservation to be
offered to those women who are at significant risk
of permanent ovarian damage before they undergo
gonadotoxic treatment such as total body irradia-
tion (TBI) or high risk chemotherapy [1]. This review
focuses on the use of antimullerian hormone (AMH)
in assessing the effects on the ovarian reserve of
these gonadotoxic treatments.
What is the ovarian reserve?
The term ovarian reserve refers to the population of
primordial (nongrowing) follicles in the ovary. It is
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REVIEW
also used as a convenient short-hand in reproduc-
tive medicine to mean the number of follicles that
can be stimulated by exogenous ‘functional’ ovarian
reserve, and to describe the reproductive potential of
a woman as a function of the number and quality of
her oocytes [2], but these usages blur the important
distinction between the true ovarian reserve and the
size of the pool of growing, generally small antral,
follicles. Although many chemotherapy regimens
result in loss of growing follicles, it is the effect
on the nongrowing pool that is important for a
woman’s future reproductive function. The number
of primordial follicles peaks in foetal life at 18–22
weeks with 300000 primordial follicles per ovary. By
birth, the number of primordial follicles in the
ovaries has already started to fall: this continues
through pre and postpubertal life with only 12
and 3% of nongrowing follicles left at 30 and
40 years of age, respectively. At menopause, only
around 1000 follicles remain [3,4].
Ovarian reserve testing with serum
antimullerian hormone
AMH is considered the best currently available bio-
marker of the ovarian reserve, although it only
reflects this indirectly [5]. It is a glycoprotein which
is produced by secondary, preantral and early antral
follicles up to 9mm diameter. Although AMH is not
produced by primordial follicles, its circulating level
is significantly correlated with them in healthy
women [6]: importantly, this is based on only a
small number of samples. There is an initial rise
in AMH shortly after birth, then a gradual continu-
ous increase throughout childhood with some fluc-
tuation around puberty with a peak at 25 years [7,8].
That AMH is readily detectable in prepubertal girls
makes it a potential useful marker [9], though its
interpretation in childhood and adolescence ismore
challenging because of the physiological rise in
AMH until age 25 [7]. Thereafter, AMH decreases
with age, and initial studies suggested that it
becomes undetectable around 5 years before meno-
pause [10]. Thus, an undetectable AMH indicates
transition to menopause. With the emergence of
more sensitive AMH assays, the interval between
undetectable AMH and last menstrual period will
be reduced but this has yet to be defined clearly.
AMH has little inter-cyclical [11] and intra-cycli-
cal variation as it reflects the number of 5–8mm
diameter rather than preovulatory follicles [12] thus
conveniently can be assessed throughout the men-
strual cycle. The most established clinical use of
AMH is prediction of ovarian response to ovarian
stimulation in assisted reproductive technology,
predicting oocyte quantity but not live birth [13].
Effects of chemotherapy on ovarian function
and antimullerian hormone
The potential use of AMH to detect a detrimental
effect of chemotherapy on ovarian function was first
described in a group of childhood cancer survivors
[14] who had lower AMH levels despite regular men-
strual cycles, compared with healthy women. The
effects of chemotherapy on AMH in women with
cancerwere subsequentlydemonstratedduring treat-
ment for breast cancer with a rapid and drastic fall
during chemotherapy and limited recovery thereaf-
ter [15]. This has since been confirmed [16–19], with
AMH often becoming undetectable after the first
cycle of chemotherapy. By the end of six cycles of
chemotherapy treatment for breast cancer, AMH is
almost undetectable in most women [17].
The degree of ovarian damage depends on the
type of chemotherapeutic agents used, cumulative
dosage and age at the time of treatment. Alkylating
agents are associated with the highest risk of gona-
dotoxicity in terms of higher risk of low AMH,
amenorrhoea and lower chance of recovery of
AMH [20,21]. AMH is undetectable and shows no
recovery in women receiving high-risk treatment:
women and children treated with alkylating agents
in high doses showed only little recovery of AMH
[9,16]. Age has an important impact, with younger
women have a higher pretreatment AMH, and a
lower risk of undetectable AMH at the end of treat-
ment chemotherapy (65% in women treated for
breast cancer aged over 40; 16% in women aged
40 years) [22&&]. Younger age and higher pretreat-
ment AMH brings a lower risk of chemotherapy-
related amenorrhoea [17,19,22
&&
,23] and higher
chance of return of menstruation [24,25]. AMH
recovery is slower in older aged women [18,22
&&
].
The rate of recovery of AMH is faster if basal AMH is
higher [16]. Pretreatment AMH therefore predicts
post-treatment recovery of ovarian function and
KEY POINTS
 Women should be made aware before receiving
treatment that ovarian damage with a fall in AMH can
occur after chemotherapy, radiotherapy that involves
the pelvis and ovarian surgery.
 Partial recovery of AMH after gonadotoxic treatment is
possible, particularly in women with a higher baseline
AMH and with low gonadotoxicity treatment.
 At present, AMH is of value for predicting
amenorrhoea and POI after these treatments, but data
on prediction of subsequent fertility are limited.
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AMH levels, which in turn indicate remaining ovar-
ian lifespan. Figure 1 illustrates the effect of gona-
dotoxic treatment on ovarian activity as reflected in
AMH levels over time [26].Women treatedwith ‘low
risk’ chemotherapy also show a fall in AMH to low
levels during treatment [27,28] but with good recov-
ery thereafter (Fig. 2). A recent analysis has however
demonstrated that recovery is limited in women
FIGURE 1. Schematic of the effect of gonadotoxic cancer treatment on ovarian function. The three lines represent women with
high, average and low ovarian reserve (as, e.g. reflected in AMH concentrations). Treatment results in a rapid fall in all
women. Those with low ovarian reserve (red line) are more likely to develop POI during treatment, and for that to persist
thereafter. Conversely, those with higher ovarian reserve will show a variable recovery, some going on to develop early POI
(blue line) with others, at the highest level of ovarian reserve (green line) showing more prolonged ovarian activity, with later
the normal age-related decline. POI, premature ovarian insufficiency. Reproduced with permission [26].
FIGURE 2. AMH concentrations at prechemotherapy, after two cycles of Doxorubicin, (Bleomycin), Vinblastine, Dacarbazine
[A(B)VD], at end of treatment and at 1, 2 and 3 years after chemotherapy. Blue, women treated with A(B)VD throughout; red,
women treated with BEACOPP after 2 cycles of A(B)VD. Mean sem. A(B)VD, Doxorubicin, (Bleomycin), Vinblastine,
Dacarbazine; AMH, antimullerian hormone. Adapted from [28].
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aged more than 35 years, with that loss of recovery
related to age and not pretreatment AMH [28].
Effects of radiotherapy on ovarian function
and antimullerian hormone
Oocytes are very sensitive to radiotherapy [29]. The
detrimental effects depend on irradiation field, dos-
age, fractionation schedule and whether the patient
is pre or post menarche. There are more limited data
on AMH after radiotherapy than after chemother-
apy. Childhood cancer survivors who received
radiotherapy to the abdomen, pelvis, sacrum and
total body have lower AMH than survivors with
irradiation to other parts of the body (<0.1mg/l
versus 1.5mg/l) [30]. Women treated with TBI for
stem cell transplant all developed premature ovar-
ian insufficiency (POI) with undetectable AMH [31],
and TBI as part of the conditioning therapy before
bone marrow transplant affects AMH more than
chemotherapy or radiotherapy for childhood malig-
nant or non-malignant disease [32].
Effects of surgery on ovarian function and
antimullerian hormone
Ovarian cysts are common in reproductive age
women, and laparoscopic ovarian cystectomy is a
recommended treatment for benign cysts [33].
There is reduction in the ovarian reserve after ovar-
ian cystectomy as evidenced by a fall in AMH [34,35]
and partial recovery in AMH is observed in some
women from 3 to 12 months after excision of endo-
metrioma [34,36–38]. The proposed mechanisms
for ovarian damage after cystectomy include inad-
vertent damage to or removal of underlying healthy
ovarian tissue during stripping of the ovarian cyst
wall [39] and two recent systematic reviews and
meta-analyses suggested that the use of bipolar dia-
thermy is associated with a greater decline of AMH
when compared with nonthermal haemostatic
methods including suturing or haemostatic sealant
[40,41
&
]. The risk of ovarian damage and fall in AMH
after cystectomy for endometrioma is greater than
after surgery for other benign ovarian cysts in some
studies. However, a recent meta-analysis reported a
similar magnitude of reduction in AMH (38%) after
both types of cystectomy [42].
A greater fall in AMH is observed after bilateral
cystectomy for endometrioma [34,35,43–45] and
with surgerywith damage to the ovarian blood supply
[43,44,46]. There is a higher chance of disruption of
the blood supply to the ovaries and therefore a greater
fall in AMHwhen cystectomy is performed in women
with a higher revised American Society of Reproduc-
tive Medicine score or when adnexal dissection
involves the mesosalpinx. AMH decline is reported
not to be associated with cyst size in most studies
[36,43,47,48]. As with data after chemotherapy,
womenwith a lower preoperative AMH have a higher
chance of developing diminished ovarian reserve
(DOR; defined as AMH<1.1ng/ml or 7.9pmol/l) after
ovariancystectomyfor endometrioma.Apreoperative
AMH less than 2.1ng/ml (15pmol/l) or less than
3.5ng/ml (25pmol/l) predicted DOR (AMH <1.1ng/
ml or 7.9pmol/l) at 6 months for unilateral and bilat-
eral cystectomy, respectively [35].
Prediction of amenorrhoea or premature
ovarian insufficiency using antimullerian
hormone
There is an increased likelihood for a healthy woman
to reachmenopause before themedian age of 51 years
if AMH is low for her age [49]. Conversely, if her AMH
level is more than 0.02ng/ml (0.14pmol/l), there is
minimal chance of menopause within 5 years regard-
lessofwomen’s age [50].Theapplicationofa lowAMH
to predict the probability ofmenopause is more sensi-
tive in late than in young reproductive age women,
but an undetectable AMH level (using a high-sensitiv-
ity assay) is predictive of menopause within 5 years in
only 60% of healthy women agedmore than 45 years
[50]. The difficulty of predicting menopause accu-
rately by using AMH seems because of the differences
in decline trajectory between differentwomen [51], as
well asothermodifiers suchas smoking, andatpresent
it remains impossible to predict age at menopause
accurately in healthy women.
The value of AMH for prediction of amenorrhoea
after gonadotoxic treatment largely derives from
studies in women receiving chemotherapy for breast
cancer. The risk of amenorrhoea can be predicted by
pretreatment AMH with the risk of persistent ame-
norrhoea higher with a lower pretreatment AMH.
Younger age and higher pretreatment AMH are two
important favourable prognostic factors for ovarian
recovery [19,52,53].WomenwithpretreatmentAMH
of less than 7.3pmol/l were 9.3 times more likely to
develop POI 2 years after chemotherapy [22
&&
]. A
mosaic chart incorporating both age and pretreat-
ment AMH level for postrecovery menstruation pre-
diction indicates that, for all premenopausal women,
an AMH level less than 3.8pmol/l predicts amenor-
rhoea, whereas AMHmore than 20.3pmol/l predicts
continuingmenstruation at 2 years (Fig. 3). For inter-
mediate values, age also becomes an important factor
[19]: larger studies are needed to validate and refine
this analysis. In women older than 40 years, an
undetectable AMH (using a highly sensitive assay)
immediatelypost-treatmentcanpredictPOIat2years
with good accuracy [22
&&
], whereas younger women
Reproductive endocrinology
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showed recovery of AMH, including from undetect-
able levels. In older women this may be a potential
guide to post-treatment endocrine therapy, but it
may not be sufficiently reliable in younger women.
Whether this can be improvedwith further improve-
ments to the sensitivity ofAMHassays is unclear, as it
will also be determined by whether there are suffi-
cient remaining nongrowing follicles (that do not
produce AMH) to support development of antral
follicles that do produce AMH. There is likely to be
a combination of assay sensitivity and time as che-
motherapy (perhaps combined with pretreatment
AMH, age and an index relating to the chemotherapy
regimen) that will reliably be able to predict ovarian
recovery versus permanent ovarian failure.
The possibility of natural conception in POI is
5–10% [54]. Fertility preservation should be offered
to those women who are at risk of irreversible ovar-
ian damage with no recovery of AMH before they
undergo gonadotoxic treatment such as TBI and
high-risk chemotherapy.
Prediction of fertility with antimullerian
hormone
Current evidence clearly demonstrates that AMH is
not a ‘fertility test’, predicting neither natural
conception in healthy women [55,56,57
&&
] nor live
birth after assisted reproduction [13]. Prospective
cohort studies involving healthy women predomi-
nantly in their 20s [56] or 30s [57
&&
] showed no
difference in fecundability between women with
low and normal ovarian reserve and between older
and younger women with DOR.
Childhood and adult cancer survivors have
reduced fertility depending on diagnosis/treatment
given [58,59], and AMH in cancer survivors is also
lower when compared with healthy women
[14,30,60].However, there is no direct evidence dem-
onstrating that a lower AMH is predictive of reduced
chance to conceive naturally after cancer treatment.
A retrospective study reported that there was no
difference in pregnancy occurrence with detectable
or undetectable post-treatment AMH in 134 women
treated with breast cancer [61]. Natural pregnancy
has been reported evenwhen AMHwas undetectable
after cancer treatment [17,62,63], althoughtheassays
used were less sensitive than current ones.
The implications of low AMH for fertility after
ovarian cystectomy for benign ovarian cyst on preg-
nancy are similarly unclear.Womenwith low preoper-
ative AMH have higher risk of DOR diagnosed
6 months after operation, and a lower cumulative
spontaneouspregnancy rate at24months afterovarian
FIGURE 3. Mosaic chart for ongoing menses (M) or chemotherapy-related amenorrhoea (A) using serum AMH and
chronological age as predictor variables. AMH, antimullerian hormone. Reproduced with permission [19].
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cystectomy for endometrioma in women with DOR
than non-DOR women (14.4 versus 59.2%) has been
reported [35]. A prospective study found that postop-
erativeAMHlevel at6monthsafterovariancystectomy
for benign ovarian cyst was not different between
pregnant and non-pregnant groups [64]. It is difficult
to draw any conclusion on the predictive value of
lowAMHafterovariancystectomyonfertilityoutcome
as most studies do not include pregnancy as an out-
come. Interpretation of results from studies reporting
pregnancy needs to be cautious as we need to know
whether thosewomenincludedinthestudies sought to
become pregnant, and the studies usually only report
pregnancy as a secondary outcome.
Other issues to consider during
interpretation of antimullerian hormone
AMH GenII ELISA assay by Beckman Coulter (Brea,
CA, USA) was the most commonly used assay until
recently, but is increasingly being replaced by auto-
mated assays. The lower limit of detection is valu-
able for analysis of the very low AMH levels often
found after chemotherapy. There is still a difference
in calibration between assays [65] which should be
taken into account if comparing studies, until an
international standard to unify the calibration
between different assays is available.
Table 1 shows the factors affecting AMH level
that should be considered before clinical application
of AMH levels in this and other contexts (reviewed
more fully in other articles in this collection).
Women with lymphoma have lower AMH at diag-
nosis than age-matchedhealthywomen andwomen
with other cancers before treatment [66]. In girls
with a range of newly diagnosed cancers, including
leukaemia, lymphoma, sarcoma, nephroblastoma
and neuroblastoma, AMH level was correlated with
general health markers, that is, pyrexia, C-reactive
protein (CRP) and anaemia [67]. Other factors likely
to be of relevance in interpreting AMH levels in this
context include BRCA-1 gene carrier and the use of
hormonal contraception. BRCA-1 gene mutation
carriers have higher risk of developing breast cancer
and their AMH is 25% lower than noncarriers [68].
Hormonal contraceptives are commonly used by
this population of young women, and additionally
as adjuvant treatment after surgery for endometri-
osis, and sometimes as hormone replacement. AMH
is 19% lower in users of combined oral contracep-
tives than in nonusers [69]. Gonadotropin hormone
releasing hormone (GnRH) agonist treatment also
reduces AMH over a period of several months [15].
CONCLUSION
A decrease in ovarian reserve with a fall in AMH can
occur after treatments including chemotherapy,
radiotherapy and ovarian surgery. In some women,
depending on age, preexisting ovarian reserve/AMH
and treatment administered, POI may result with
undetectable AMH after treatment and without
recovery. Clinicians should be aware of such effect
and include discussionof thepossible implicationsof
decreased AMH on ovarian reserve and fertility with
women before undergoing treatment. The accurate
interpretation of post-treatmentAMH level on repro-
ductive lifespan and fertility prediction needs larger
prospective studies with longer follow-up.
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